Acetamenophen composition with reduced liver toxicity

Details Acetamenophen composition with reduced liver toxicity Acetamenophen composition with reduced liver toxicity

1998-09-29

2000-04-11

Ware, Todd D

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

424451, 424464, A61K 900, A61K 948, A61K 920

Patent

active

06048540&

DESCRIPTION:

BRIEF SUMMARY
TECHNICAL FIELD

The present invention relates to new analgesic composition comprising acetaminophen, aspartic acid and methionine, to obtain the alleviation of liver toxicity and the release of hangover as well as an analgesic effect.


BACKGROUND ART

Acetaminophen is a typical antipyretic and analgesic agent which is used frequently instead of aspirin. However, liver toxicity of acetaminophen is recently on the rise as intensive side effect, and has been reported in many articles. The high dose administration of that induces acute liver toxicity. And especially to the patient of alcoholic liver dysfunction, a infant and indeed even a normal healthy person in the case of long-time multiple dosing, it is known that the usual dose administration of acetaminophen also induces widespread liver toxicity and can induce ophthalmic disease such as cataract. Besides, it is worried that a normal healthy person can get liver toxicity induced by acetaminophen because a modern usually takes much alcoholic drink for the release of stress coming from his place of work, etc. Acetaminophen administrated at the condition of liver function weakened by alcohol may induces severe liver toxicity with acceleration effect, and may bring about the retardation of recovery from hangover.
It gets known that the liver toxicity of acetaminophen related to medicines administered together. Alcohol and medicines of barbital family, representatively, increase severely the liver toxicity of acetaminophen through the liver enzyme induction. Especially, it was reported that only usual dose administration of acetaminophen induced a pathological change of liver cell in an alcoholic poisoning person as well as high dose administration of acetaminophen after drinking of alcohol induces severe liver toxicity (J. Biol. Chem., 271(20), 12063; Biochem. Pharmacol., 50(11), 1743; Gastorenterol., 109(6), 1907; Hapatol., 22(3), 767). At low dose, only about 2% of acetaminophen is eliminated as unmetabolized form, and most of that is eliminated as inactive metabolites of sulfonated form (20.about.30%), glucuronic acid conjugation (45.about.55%), and cysteine and mercaptouric acid conjugation (15.about.55%). However, liver enzyme induction agent such as alcohol and barbital, and acetaminophen of high dose increase the activity of cytochrome P-450 in liver cell and bring about production of intensive alkylation agent, that is, active metabolite N-acetly-p-benzoquinoneimine (NAPQI) as well as main metabolite, that is, inactive metabolite. NAPQI produced is inactivated through the conjugation with glutathione, but if the glutathione is depleted, NAPQI binds with --SH group of cell protein and, therefore, induces liver toxicity through alkylation or oxidation.
The agents that can alleviate liver toxicity of acetaminophen are chemicals such as cysteamine, methionine, cysteine, dimethylmercaptol, selenium, tocopherol, ascorbic acid, etc. They can alleviate liver toxicity at various efficacy range of acetaminophen. These chemicals have antioxidation effect commonly and it is proposed that liver toxicity of acetaminophen is alleviated through these antioxidation effects. However, it is known that butylhydroxytoluene, butylhydroxyanisol, etc., which are the representative antioxidants and food additives, increase liver toxicity of acetaminophen and until now the relation of the antioxidation process and the alleviation effect of liver toxicity of acetaminophen did not become clear. Recently, it is concerned about each action mechanisms of such chemicals. In said chemicals having antioxidation effect, thiol compounds (having --SH group) such as methionine, cysteamine, cysteine, dimethylmercaptol, etc. act as precursor of glutathione, and it is known that they can be used for prevention and treatment of liver toxicity of acetaminophen. These thiol compounds alleviate the liver toxicity of acetaminophen by producing glutathiones which conjugate and convert NAPQI, active metabolite of acetaminophen, into inactive metabolite.
Until now many studies, for example, paten

REFERENCES:
patent: 4314989 (1982-02-01), Rosen
patent: 4562024 (1985-12-01), Rogerson
patent: 4631284 (1986-12-01), Salpekar et al.
patent: 5562919 (1996-10-01), Doty et al.
patent: 5716991 (1998-02-01), Jones
S.S. Lee et al., "Role of CYP2E1 in the Hepatotoxicity of Acetaminophen," J. Biol. Chem, 271:12063-12067 (1996).
V. E. Kostrubsky et al., "Acute Hepatotoxicity of Acetaminphen in Rats Treated with Ethanol Plus Isopentanol," Biochem. Pharma., 20:1743-1748 (1995).
A. J. Makin et al., "Liver, Pancreas, and Biliary Tract: A 7-Year Experience of Severe Acetaminophen-Induced Hepatotoxicity (1987-1993)," Gastroenterology, 109:1907-1916 (1995).
H. J. Zimmerman and W. C. Maddrey, "Acetaminophen (Paracetamol) Hepatotoxicity With Regular Intake of Alcohol: Analysis of Instances of Therapeutic Misadventure," Hepatology, 22:767-773 (1995).

Affiliated with

Also associated with

Rating

Acetamenophen composition with reduced liver toxicity does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Acetamenophen composition with reduced liver toxicity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Acetamenophen composition with reduced liver toxicity will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1174565